Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01751425 |
| Title | Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | M.D. Anderson Cancer Center|Incyte Corporation |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | United States | Details |